A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Late effects of treatment of non-Hodgkin lymphoma (NHL) have been observed. Impaired fertility may occur after exposure to alkylating agents.[1] For as many as three decades after diagnosis, patients are at a significantly elevated risk of developing second primary cancers, especially the following:[2-5]
Lung cancer.
Brain cancer.
Kidney cancer.
Bladder cancer.
Melanoma.
Hodgkin lymphoma.
Acute nonlymphocytic leukemia.
Left ventricular dysfunction was a significant late effect in long-term survivors of high-grade NHL who received more than 200 mg/m² of doxorubicin.[1,6]
Myelodysplastic syndrome and acute myelogenous leukemia are late complications of myeloablative therapy with autologous bone marrow or peripheral blood stem cell support, as well as conventional chemotherapy-containing alkylating agents.[3,7-14] Most of these patients show clonal hematopoiesis even before the transplant, suggesting that the hematologic injury usually occurs during induction or reinduction chemotherapy.[9,15,16] A series of 605 patients who received autologous bone marrow transplant (BMT) with cyclophosphamide and total-body radiation therapy (as conditioning) were followed for a median of 10 years. The incidence of a second malignancy was 21%, and 10% of those malignancies were solid tumors.[17]
A study of young women who received autologous BMT reported successful pregnancies with children born free of congenital abnormalities.[18] Late-occurring venous thromboembolism can occur after allogeneic or autologous BMT.[19]
Some patients have osteopenia or osteoporosis at the start of therapy; bone density may worsen after therapy for lymphoma.[20]
Sources: 20
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lymphoma associated with the CD30 antigen. The translocation of chromosomes 2 and 5 creates a unique fusion protein with a nucleophosmin–anaplastic lymphoma kinase (ALK).[1,2] Patients whose lymphomas express ALK by immunohistochemistry are usually younger and may have systemic symptoms, extranodal disease, and advanced-stage disease. However, they have a more favorable survival rate than patients with ALK-negative disease.[3,4] ALK-negative ALCL has been further characterized by DUSP22 chromosomal rearrangements and the presence of TP63 pathogenic variants. While DUSP22 rearrangements are associated with improved prognosis, TP63 pathogenic variants are associated with poorer outcomes.[5]
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
A prospective randomized trial included 452 patients with CD30-positive T-cell lymphoma (CD30 expression >10%). Of these patients, 70% had ALCL (22% with ALK-positive disease and 48% with ALK-negative disease). The trial compared the previously used standard regimen, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), with brentuximab vedotin (an anti-CD30 monoclonal antibody conjugated to a cytotoxic agent) combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP regimen).[6]
Sources: 6
A prospective randomized trial included 452 patients with CD30-positive T-cell lymphoma (CD30 expression >10%). Of these patients, 70% had ALCL (22% with ALK-positive disease and 48% with ALK-negative disease). The trial compared the previously used standard regimen, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), with brentuximab vedotin (an anti-CD30 monoclonal antibody conjugated to a cytotoxic agent) combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP regimen).[6]
With a median follow-up of 47.6 months, the 5-year overall survival (OS) rates were 70.1% (95% confidence interval [CI], 63.3%–75.9%) for patients who received A+CHP and 61.0% (95% CI, 54.0%–67.3%) for patients who received CHOP (hazard ratio [HR], 0.72; 95% CI, 0.53–0.99).[7][Level of evidence A1]
Sources: 7 · Level of evidence A1
The 5-year progression-free survival (PFS) rates were 51.4% (95% CI, 42.8%–59.4%) for patients who received A+CHP and 43.0% (95% CI, 35.8%–50.0%) for patients who received CHOP (HR, 0.70; 95% CI, 0.53–0.91).
This established A+CHP as a new option for patients with ALCL or other CD30-positive T-cell lymphomas, such as angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.
For patients with relapsed disease, anecdotal responses have been reported for brentuximab vedotin,[8-11] belinostat,[12] romidepsin,[13] and pralatrexate.[14][Level of evidence C3]
In a phase II study (NCT00866047), 66% of 58 patients attained a complete response with brentuximab vedotin.[11]
Sources: NCT00866047 · 11
In a phase II study (NCT00866047), 66% of 58 patients attained a complete response with brentuximab vedotin.[11]
At a median follow-up of 58 months, the 5-year PFS rate was 57% (95% CI, 41%–74%), and the 5-year OS rate was 79% (95% CI, 65%–92%). Of the patients achieving a complete response, 42% underwent hematopoietic stem cell transplant (SCT).[11][Level of evidence C3]
Sources: 11 · Level of evidence C3
In a retrospective review, 39 patients with relapsed disease had a 3-year PFS rate of 50% after autologous or allogeneic SCT.[15][Level of evidence C2]
Sources: 15 · Level of evidence C2
A retrospective review of 84 patients with ALK-negative ALCL suggested a survival benefit with autologous SCT. This hypothesis requires confirmation in a randomized prospective trial.[16][Level of evidence C3]
Sources: 16 · Level of evidence C3
A retrospective study included 182 patients with relapsed or refractory ALCL (23% ALK-positive, 21% ALK-negative, and 56% ALK-unknown) who underwent allogeneic SCT.[17]
Sources: 17
A retrospective study included 182 patients with relapsed or refractory ALCL (23% ALK-positive, 21% ALK-negative, and 56% ALK-unknown) who underwent allogeneic SCT.[17]
The 5-year PFS rate was 41% (95% CI, 34%–49%), and the 5-year OS rate was 41% (95% CI, 49%–64%).[17][Level of evidence C3]
Sources: 17 · Level of evidence C3
On multivariate analysis, African American race (HR, 2.7; 95% CI, 1.6–4.8; P < .001) and refractory disease at time of allogeneic SCT (HR, 3.2; 95% CI, 1.6–6.2; P < .001) were predictive factors for inferior OS.
Despite ALK positivity being a favorable prognostic factor, outcomes after allogeneic SCT in this study did not vary significantly according to ALK status.
ALCL in children is usually characterized by systemic and cutaneous disease and has high response rates and good OS with doxorubicin-based combination chemotherapy.[18] The ALK inhibitor crizotinib has been combined with chemotherapy for previously untreated pediatric patients, and crizotinib has been used to control disease in multiply relapsed pediatric patients.[19,20] Crizotinib is associated with a high risk (around 25%) of thromboembolism, especially pulmonary embolism, and prophylaxis is recommended. There are no reports supporting the use of crizotinib in adults.
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Patients with breast implant–associated ALCL may do well without chemotherapy after capsulectomy and implant removal if the disease is confined to the fibrous capsule, and no associated mass or lymphadenopathy is present.[21-24] Most patients with breast implant–associated ALCL have a characteristic deletion at 20Q13.13 that may help to diagnostically distinguish it from cutaneous or systemic ALCL.[25]
Primary cutaneous ALCL is a distinct entity that is typically ALK-negative and has a very indolent/low-grade clinical course. Breast implant–associated ALCL almost always occurs with implants that have a textured surface (so-called macrotextured implants) that helps adhere to the breast. Warnings, suspensions, and bans of macrotextured implants have occurred worldwide. The risk of breast implant–associated ALCL is approximately 1 in 12,000 people, but this risk may rise with further follow-up.[26]
Sources: 26
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
The 2016 World Health Organization (WHO) classification recognized nodal lymphomas of T follicular helper (TFH) cell origin as a distinct subset of peripheral T-cell lymphoma (PTCL). Unified by a CD4+ TFH cell origin, this subset includes:[1]
Sources: 1
Angioimmunoblastic T-cell lymphoma (AITL or ATCL).
Follicular peripheral T-cell lymphoma (F-PTCL).
Nodal peripheral T-cell lymphoma with follicular helper phenotype (nodal PTCL with TFH phenotype).
AITL is the most common of these entities and is the second-most common subtype of PTCL.[2-5] Patients often present with profound lymphadenopathy, fever, night sweats, weight loss, skin rash, a positive Coombs test, and polyclonal hypergammaglobulinemia.[6] Opportunistic infections are frequent because of an underlying immune deficiency. B-cell Epstein-Barr virus genomes are detected in most affected patients.[7] For more information about weight loss, see Nutrition in Cancer Care and for more information about skin rash, see Pruritus.
Sources: 2 · 5 · 6 · 7 · Nutrition in Cancer Care · Pruritus
The remaining subtypes of nodal lymphomas of TFH cell origin, including F-PTCL and nodal PTCL with TFH phenotype, are derived from the same cell of origin. However, unlike AITL, these subtypes are not associated with hypervascularity on nodal biopsy and often lack the hyperinflammatory symptoms characteristic of AITL.[1]
Sources: 1
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Doxorubicin-based combination chemotherapy, such as the CHO(E)P regimen (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), is commonly used for patients with AITL and other nodal lymphomas of TFH cell origin.[2,5] For CD30-positive cases, brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone is the proposed standard of care.[8][Level of evidence C3] Patients with AITL were included in a clinical trial involving mostly patients with anaplastic large cell lymphoma. A benefit for this smaller AITL subgroup cannot be established.[8,9][Level of evidence C3] For more information, see the Treatment of Anaplastic Large Cell Lymphoma section.
Sources: 2 · 5 · 8 · Level of evidence C3 · 8 · 9 · Level of evidence C3 · Treatment of Anaplastic Large Cell Lymphoma
The International Peripheral T-Cell Lymphoma Project involving 22 international centers identified 243 patients with AITL. The 5-year overall survival rate was 33%, and the failure-free survival rate was 18%.[10] Myeloablative chemotherapy and radiation therapy with autologous or allogeneic peripheral stem cell support has been described in anecdotal reports.[11-16][Level of evidence C3] Anecdotal responses have been reported for patients who received cyclosporine,[17] pralatrexate,[18] bendamustine,[19] belinostat,[20] the histone deacetylase inhibitor romidepsin, hypomethylating agents (HMAs),[21,22] and brentuximab vedotin (even if there is little or no CD30 expression on the lymphoma).[23,24][Level of evidence C3] Occasional spontaneous remissions and protracted responses to steroids only have been reported. Given increased frequency of pathogenic variants in genes that regulate epigenetic modification—such as TET2, IDH2, and DNMT3A—there is increased interest in therapies targeting these aberrations with HMAs and histone deacetylase inhibitors with anecdotal reports of improved efficacy compared with other subsets of PTCL.[21,22,25][Level of evidence C3] Further studies are needed to better characterize the efficacy of this approach.[21,22,25]
Sources: 10 · 11 · 16 · Level of evidence C3 · 17 · 18 · 19 · 20 · 21 · 22 · 23 · 24 · Level of evidence C3 · 21 · 22 · 25 · Level of evidence C3 · 21 · 22 · 25
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Patients with peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have diffuse large cell or diffuse mixed lymphoma that expresses a cell surface phenotype of a postthymic (or peripheral) T-cell expressing either CD4 or, less often, CD8.[1] PTCL-NOS encompasses a group of heterogeneous nodal T-cell lymphomas that will require future delineation.[2,3] Gene expression profiling studies have identified two distinct subtypes of PTCL-NOS based on the transcription factors GATA3 and TBX21. Early investigation and anecdotal reports suggest these subtypes may carry important prognostic implications and could predict response to certain therapies.[4] Additional studies are needed for further characterization of their clinical relevance.
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Most investigators report worse response and survival rates for patients with PTCL-NOS than for patients with comparably staged B-cell aggressive lymphomas.[3,5] Most patients present with multiple adverse prognostic factors (i.e., older age, stage IV, multiple extranodal sites, and elevated lactate dehydrogenase), and these patients have low (<20%) failure-free survival and overall survival (OS) rates at 5 years.[3,5] As with other lymphomas (e.g., diffuse large B-cell lymphoma [DLBCL] or follicular lymphoma), event-free survival (EFS) at 24 months predicts a 5-year OS rate of 78%.[6]
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Therapy involves doxorubicin-based combination chemotherapy such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHO(E)P (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone). Doses are the same as those used for DLBCL.[7] For CD30-positive cases, brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone is the proposed standard of care.[8][Level of evidence C3] Patients with PTCL-NOS were included in the clinical trial involving mostly patients with anaplastic large cell lymphoma. A benefit for this smaller PTCL-NOS subgroup cannot be established.[8,9][Level of evidence C3] For more information, see the Treatment of Anaplastic Large Cell Lymphoma section.
Sources: 7 · 8 · Level of evidence C3 · 8 · 9 · Level of evidence C3 · Treatment of Anaplastic Large Cell Lymphoma
For patients with early-stage disease, anecdotal retrospective series disagree on the value of consolidative radiation therapy after combination chemotherapy.[10][Level of evidence C3] Consolidation therapy using high-dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplant (SCT) has been given to patients with advanced-stage PTCL after induction therapy in multiple phase II or retrospective trials. Evidence for this approach is anecdotal.[11-18][Level of evidence C3]
Sources: 10 · Level of evidence C3 · 11 · 18 · Level of evidence C3
Evidence (CHOP, CHO[E]P, or other options for relapsing disease):
A randomized prospective trial included 104 patients younger than 61 years with stage II, III, or IV PTCL (excluding ALK-positive anaplastic large cell lymphoma). Patients received either autologous SCT or allogeneic SCT as consolidation therapy after induction with CHO(E)P followed by DHAP (dexamethasone, cytarabine, and cisplatin).[19][Level of evidence C3]
Sources: 19 · Level of evidence C3
A randomized prospective trial included 104 patients younger than 61 years with stage II, III, or IV PTCL (excluding ALK-positive anaplastic large cell lymphoma). Patients received either autologous SCT or allogeneic SCT as consolidation therapy after induction with CHO(E)P followed by DHAP (dexamethasone, cytarabine, and cisplatin).[19][Level of evidence C3]
With a median follow-up of 42 months, the 3-year EFS rate was 43% for patients who received allogeneic SCT and 38% for patients who received autologous SCT.
The 3-year OS rate was 57% for patients who received allogeneic SCT and 70% for patients who received autologous SCT (P = nonsignificant).
None of the 21 responding patients who proceeded to allogeneic SCT relapsed, and 36% of patients who proceeded to autologous SCT relapsed.
Eight of 26 patients (31%) who received allogeneic SCT died of graft-versus-host disease, and none of the 41 patients who received autologous SCT died of toxicity.
The benefit of graft-versus-lymphoma effect was negated by increased transplant-related mortality.
In a prospective trial of 109 evaluable patients with relapsing disease, treatment with pralatrexate resulted in a 30% response rate and a median 10-month duration of response.[20,21][Level of evidence C3]
Sources: 20 · 21 · Level of evidence C3
Similar response rates were seen in 130 evaluable patients with relapsing disease who received romidepsin in a prospective trial.[21][Level of evidence C3]
Sources: 21 · Level of evidence C3
Anecdotal responses have been seen with a combination of pralatrexate and romidepsin,[22] single-agent bendamustine,[23] belinostat,[24] and brentuximab vedotin (even if there is little or no CD30 expression on the lymphoma).[25][Level of evidence C3]Incorporation of these new agents with CHOP chemotherapy is under clinical evaluation.[3,8]
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Extranodal natural killer (NK)/T-cell lymphoma, nasal type, is an aggressive lymphoma marked by extensive necrosis and angioinvasion, most often presenting in extranodal sites, in particular the nasal or paranasal sinus region.[1] Other extranodal sites include the palate, trachea, skin, and gastrointestinal tract. Hemophagocytic syndrome may also occur; historically, these tumors were considered part of lethal midline granuloma.[2] Tumor cells are typically NK cells with immunophenotyping showing CD3 and CD56 expression. In nearly all cases, Epstein-Barr virus (EBV) is detectable in the tumor cells. Aggressive NK cell leukemia (ANKL) is a separate but related diagnosis, which was previously recognized as a subset of large granular lymphocyte (LGL) leukemia, and is characterized by mature NK cell neoplastic involvement of the blood or marrow involvement with a particularly aggressive course and poor prognosis.[3] A benign NK-cell enteropathy (EBV negative) on endoscopic biopsy can be distinguished from NK/T-cell lymphoma.[3] Extranodal NK-cell lymphoma (ENKL), nasal type is rare in Western countries and more commonly seen in Asia, where it represents 3% to 8% of all lymphoma cases. Most cases present with nasal involvement and localized disease. Both extranasal and advanced-stage (stages III–IV) disease are associated with poor prognosis.[4,5]
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
The management of localized ENKL with nasal involvement involves combined modality therapy with chemotherapy and radiation therapy for those fit for chemotherapy or radiation therapy alone for those unfit for chemotherapy. The management of nonlocalized nasal ENKL and all cases of extranasal ENKL involves combination chemotherapy with or without radiation therapy.[6] Because ENKL frequently expresses P-glycoprotein which confers multidrug resistance and reduces the efficacy of traditional anthracycline-based regimens, asparaginase is typically incorporated into the chemotherapy regimens.[7,8] Various asparaginase-based combination chemotherapy regimens have been used.
Evidence (asparaginase-based combination chemotherapy):
A phase II study included 28 patients with newly diagnosed stage IV or relapsed or refractory ENKL. Patients received steroids, methotrexate, ifosfamide, [L-]asparaginase, and etoposide (SMILE).[9] Despite no head-to-head studies, this regimen is used more often in clinical practice, in patients with advanced-stage disease, or in combination with radiation therapy for patients with localized disease. Other asparaginase-based regimens which have been studied include gemcitabine, oxaliplatin, and pegaspargase (P-GEMOX);[10] gemcitabine, etoposide, pegaspargase, and dexamethasone (GELAD);[11] and dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP).[12]For patients who may not tolerate or who have reactions to asparaginase, a nonasparaginase regimen may be given with concurrent radiation therapy.[13][Level of evidence C3]
A phase II study included 28 patients with newly diagnosed stage IV or relapsed or refractory ENKL. Patients received steroids, methotrexate, ifosfamide, [L-]asparaginase, and etoposide (SMILE).[9] Despite no head-to-head studies, this regimen is used more often in clinical practice, in patients with advanced-stage disease, or in combination with radiation therapy for patients with localized disease. Other asparaginase-based regimens which have been studied include gemcitabine, oxaliplatin, and pegaspargase (P-GEMOX);[10] gemcitabine, etoposide, pegaspargase, and dexamethasone (GELAD);[11] and dexamethasone, cisplatin, gemcitabine, and pegaspargase (DDGP).[12]For patients who may not tolerate or who have reactions to asparaginase, a nonasparaginase regimen may be given with concurrent radiation therapy.[13][Level of evidence C3]
The overall response rate after two cycles was 79% (95% confidence interval [CI], 65%–89%), and the complete response rate was 45%. The 1-year overall survival (OS) rate was 55% (95% CI, 38%–69%).
Grade 4 neutropenia was observed in 92% of patients, and grade 3 or 4 infections were seen in 61% of patients.[9]
Sources: 9
A modification to the SMILE regimen (mSMILE) incorporating pegylated asparaginase has demonstrated reduced toxicity.[10]
Sources: 10
A retrospective study (NCT02733458) included 35 patients with newly diagnosed stage III to IV, relapsed, or refractory ENKL. Patients received P-GEMOX.[10]
Sources: NCT02733458 · 10
A retrospective study (NCT02733458) included 35 patients with newly diagnosed stage III to IV, relapsed, or refractory ENKL. Patients received P-GEMOX.[10]
The overall response rate was 80.0%, and the complete response rate was 51.4%. The 3-year progression-free survival (PFS) rate was 38.6%, and the 3-year OS rate was 64.7%.[10][Level of evidence C3]
Sources: 10 · Level of evidence C3
A prospective multicenter study (NCT02733458) included 52 patients with newly diagnosed stage IE/IIE ENKL who received two cycles of GELAD followed by intensity-modulated radiotherapy (50–56 Gy in 25–58 fractions) and two additional courses of GELAD.[11]
Sources: NCT02733458 · 11
A prospective multicenter study (NCT02733458) included 52 patients with newly diagnosed stage IE/IIE ENKL who received two cycles of GELAD followed by intensity-modulated radiotherapy (50–56 Gy in 25–58 fractions) and two additional courses of GELAD.[11]
With a median follow-up of 32 months, the estimated 4-year OS rate was 94.2% (95% CI, 83.2%–93.1%), and the 4-year PFS rate was 90.4% (95% CI, 78.4%–95.9%).[11][Level of evidence C3]
Sources: 11 · Level of evidence C3
The overall response rate was 94.2%, and the complete response rate was 92.3%.
A retrospective study included 80 patients with newly diagnosed (n = 48), refractory (n = 23), or first-relapse (n = 9) ENKL. Patients received DDGP.[12]
Sources: 12
A retrospective study included 80 patients with newly diagnosed (n = 48), refractory (n = 23), or first-relapse (n = 9) ENKL. Patients received DDGP.[12]
The overall response rate was 91.3% (95% CI, 85.0%–96.3%), and the complete response rate was 60.0% (95% CI, 48.8%–71.3%). The 2-year PFS rate was 81.4% (95% CI, 76.3%–86.5%), and the 2-year OS rate was 87.1% (95% CI, 83.4%–91.4%).[12][Level of evidence C3]
Sources: 12 · Level of evidence C3
A phase I/II study of 27 patients with newly diagnosed stage IE or contiguous IIE disease studied the nonasparaginase-based regimen DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin). Patients received three cycles of DeVIC at the recommended phase II dosing and concurrent radiotherapy dosed at 50 Gy.[13]
Sources: 13
A phase I/II study of 27 patients with newly diagnosed stage IE or contiguous IIE disease studied the nonasparaginase-based regimen DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin). Patients received three cycles of DeVIC at the recommended phase II dosing and concurrent radiotherapy dosed at 50 Gy.[13]
With a median follow-up of 32 months, the 2-year OS rate was 78% (95% CI, 57%–89%). The overall response rate was 81%, and the complete response rate was 77%.[13][Level of evidence C3]
Sources: 13 · Level of evidence C3
The most common grade 3 or higher nonhematologic toxicity was mucositis related to radiation, which occurred in 30% of patients.
Radiation therapy is an essential component of treatment for localized ENKL, nasal type, whether given as a monotherapy or as part of combined modality therapy.
Evidence (radiation therapy with or without chemotherapy):
A retrospective review included 1,273 patients with early-stage disease. Patients were stratified into a low-risk group and high-risk group using stage, age, lactate dehydrogenase level, performance status, and primary tumor invasion.
A retrospective review included 1,273 patients with early-stage disease. Patients were stratified into a low-risk group and high-risk group using stage, age, lactate dehydrogenase level, performance status, and primary tumor invasion.
Low-risk patients fared best with radiation therapy alone,[14] while high-risk patients fared best with a strategy of radiation therapy combined with chemotherapy.[15-17][Level of evidence C3]
Sources: 14 · 15 · 17 · Level of evidence C3
A retrospective review included 303 previously untreated patients from an international consortium who received nonanthracycline chemotherapy.[18]
Sources: 18
A retrospective review included 303 previously untreated patients from an international consortium who received nonanthracycline chemotherapy.[18]
The OS rates were identical (72%−74% at 5 years) for patients with early-stage disease who received either concurrent chemotherapy and radiation therapy or chemotherapy followed by radiation therapy.[18][Level of evidence C3]
Sources: 18 · Level of evidence C3
Higher doses of radiation therapy administered at more than 50 Gy are associated with improved outcomes according to anecdotal reports.[17] The highly aggressive course, with poor response and short survival with standard therapies, especially for patients with advanced-stage disease or extranasal presentation, has led some investigators to recommend autologous or allogeneic peripheral stem cell transplant consolidation.[19-24][Level of evidence C3]
Sources: 17 · 19 · 24 · Level of evidence C3
For patients with relapsed or refractory disease, therapies targeting programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) have demonstrated promising results.
Evidence (immunotherapy):
In a phase II trial, the anti–PD-L1 antibody avelumab was given to 21 patients with relapsed or refractory disease.[25]
Sources: 25
In a phase II trial, the anti–PD-L1 antibody avelumab was given to 21 patients with relapsed or refractory disease.[25]
The complete response rate was 24%, and the overall response rate was 38%. The responses correlated with tumor PD-L1 expression.[25][Level of evidence C3]
Sources: 25 · Level of evidence C3
Treatment with pembrolizumab, an anti–PD-1 antibody, resulted in similar responses in patients with relapsed or refractory disease.[26][Level of evidence C3]
Sources: 26 · Level of evidence C3
A single-arm multicenter phase II study (GEMSTONE-201 [NCT03595657]) included 80 patients with relapsed or refractory ENKL. Patients received the anti–PD-L1 monoclonal antibody sugemalimab.
Sources: GEMSTONE-201
A single-arm multicenter phase II study (GEMSTONE-201 [NCT03595657]) included 80 patients with relapsed or refractory ENKL. Patients received the anti–PD-L1 monoclonal antibody sugemalimab.
The objective response rate was 44.9% (95% CI, 33.6%–56.6%), and the complete response rate was 35.9%. The 12-month duration of response rate was 82.5% (95% CI, 62.0%–92.6%).[27][Level of evidence B3]
Sources: 27 · Level of evidence B3
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Enteropathy-associated T-cell lymphoma (EATL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) are rare subsets of peripheral T-cell lymphoma (PTCL) which together account for less than 5% of PTCL. EATL (sometimes referred to as type 1 EATL) is a complication of celiac disease and is more common in Europe. MEITL (sometimes referred to as type 2 EATL) is not associated with celiac disease and is more common in Asia. SETD2 pathogenic variants and, to a lesser extent, STAT5B pathogenic variants are seen in most cases of EATL and MEITL.[1,2] Because a gluten-free diet prevents the development of lymphoma in patients with celiac disease, patients diagnosed in childhood rarely develop EATL. The diagnosis of celiac disease is usually made by finding villous atrophy in the resected intestine. Surgery is often required for diagnosis and to avoid perforation during therapy.[3]
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Recommended management includes CHO(E)P (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), but relapse is common and outcomes are generally poor.[4-6] Complications of treatment include gastrointestinal bleeding, small bowel perforation, and enterocolic fistulae. Patients often require parenteral nutrition. For more information on parenteral nutrition, see Nutrition in Cancer Care. Multifocal intestinal perforations and visceral abdominal involvement are seen at the time of relapse. Consolidation with either high-dose chemotherapy with autologous stem cell rescue or allogeneic stem cell transplant is often used in first or later remission.[4,7,8][Level of evidence C3] Evidence for this approach is anecdotal.
Sources: 4 · 6 · Nutrition in Cancer Care · 4 · 7 · 8 · Level of evidence C3
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
In contrast to the more aggressive forms of T-cell lymphoma with intestinal involvement, indolent T-cell lymphoma of the gastrointestinal tract (iTCL-GI) often presents more indolently. iTCL-GI can be difficult to distinguish from inflammatory bowel disease or other autoimmune disorders with gastrointestinal involvement.[1,2]
iTCL-GI is often diagnosed when multiple biopsies from different sites show matching clones by T-cell receptor gene rearrangement testing. While the immunophenotype can vary (iTCL-GI is frequently CD4+ but can also be CD8+ or CD4-/CD8-), Ki-67 is typically very low at 5% to 10%. Unlike some other intestinal lymphomas, Epstein-Barr encoding region staining for Epstein-Barr virus is usually negative. Although initial reports of this rare entity suggested a low likelihood of transformation to a more aggressive process, transformation to peripheral T-cell lymphoma, not otherwise specific and other aggressive forms has since been documented.[3]
Sources: 3
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Response to multiagent chemotherapy is limited, and many patients can be managed with watchful waiting alone. Limited studies suggest that alterations in the JAK/STAT pathway or genes involved in epigenetic modification could serve as potential therapeutic targets.[4]
Sources: 4
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of peripheral T-cell lymphoma (PTCL) comprising approximately 1% of PTCL. HSTCL often involves young men. HSTCL appears to be localized to the hepatic and splenic sinusoids, with cell surface expression of the gamma delta T-cell receptor.[1-3] Characteristic chromosomal abnormalities such as isochromosome 7q and trisomy 8 are also suggestive of the diagnosis.[4] While in most cases the neoplastic cells express a gamma delta T-cell receptor (hepatosplenic gamma delta T-cell lymphoma), there are reports of alpha beta T-cell receptor expression (hepatosplenic alpha beta T-cell lymphoma).[5] This lymphoma has an extremely poor prognosis and an extremely aggressive clinical course.
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
HSTCL is treated with induction chemotherapy and stem cell transplant (SCT) consolidation.[3,6]
Evidence (induction chemotherapy and SCT consolidation):
A meta-analysis of 118 patients with HSTCL compared CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP-like induction regimens.[7]
Sources: 7
A meta-analysis of 118 patients with HSTCL compared CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP-like induction regimens.[7]
Non–CHOP-based regimens (containing cytarabine, etoposide, and/or platinum-based treatment) were associated with improved outcomes, including an overall response rate of 82% versus 52% (P = .006) and a median overall survival (OS) of 36.5 months versus 18 months (P = .00014).
Consolidation with allogeneic SCT was associated with an improved median OS of 33 months, versus 27 months (P = .016) for autologous SCT.[7][Level of evidence C3]
Sources: 7 · Level of evidence C3
The use of ICE (ifosfamide, carboplatin, and etoposide) or IVAC (ifosfamide, etoposide, and high-dose cytarabine) has resulted in improved responses when compared with CHOP in other smaller studies as well.[8][Level of evidence D] Given the inadequate responses to CHOP or CHOP-like regimens, many clinicians are using ICE chemotherapy as front-line induction therapy, followed by consolidative allogeneic SCT for patients achieving a first remission. However, the efficacy of this approach is undetermined.
Sources: 8 · Level of evidence D
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Adult T-cell leukemia/lymphoma (ATL) is caused by infection with the retrovirus human T-lymphotrophic virus 1 (HTLV1) and is frequently associated with lymphadenopathy, hypercalcemia, circulating leukemic cells, bone and skin involvement, hepatosplenomegaly, a rapidly progressive course, and poor response to combination chemotherapy.[1,2] HTLV1 is endemic to Japan (especially the southern island of Kyushu), central Africa, the Caribbean islands, and some regions of Central and South America, the Middle East, and Australia. This retrovirus is mostly spread by sexual contact or breastfeeding.[3] ATL has been divided into four clinical subtypes:[3]
Acute (aggressive course with leukemia, with or without extranodal or nodal involvement).
Lymphoma (aggressive course with lymphadenopathy and no leukemia).
Chronic (indolent course with leukemia and lymphadenopathy).
Smoldering (indolent course with only leukemia).
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for ATL include:
Biological and targeted therapies.
Sources: Biological and targeted therapies
Brentuximab vedotin.
Sources: Brentuximab vedotin
Lenalidomide.
Sources: Lenalidomide
Valemetostat.
Sources: Valemetostat
Zidovudine and interferon alfa.
Sources: Zidovudine and interferon alfa
Cytotoxic chemotherapy and allogeneic stem cell transplant (SCT).
Sources: Cytotoxic chemotherapy and allogeneic stem cell transplant (SCT)
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
The anti-CCR4 monoclonal antibody mogamulizumab has a targeted lysis of the ATL clone and also reduces the immunosuppressive Treg population, allowing improvement of cell-mediated immunotherapy.[4] Single-agent phase II trials in patients with ATL showed response rates ranging from 30% to 50%.[5-7][Level of evidence C3] In a phase II study that combined mogamulizumab with combination chemotherapy, 101 patients had an overall response rate of 65% (95% confidence interval [CI], 55%–75%), a median progression-free survival of 7.4 months (95% CI, 5.7–9.1), and a median overall survival (OS) of 16 months (95% CI, 10.3–21.8).[8][Level of evidence C3]
Sources: 4 · 5 · 7 · Level of evidence C3 · 8 · Level of evidence C3
A retrospective review evaluated mogamulizumab combined with both the VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone; doxorubicin, ranimustine, prednisone; vindesine, etoposide, carboplatin, prednisone) regimen and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-based regimens versus chemotherapy alone. The review concluded that the 4-year OS rate was 46.3% in the mogamulizumab combination groups, compared with 20.6% in the chemotherapy-alone group.[9][Level of evidence C3] The best results were seen with CHOP-based regimens. Mogamulizumab is available in the United States but has not been approved by the U.S. Food and Drug Administration (FDA) for patients with ATL.
Sources: 9 · Level of evidence C3
Mogamulizumab is often avoided in patients planning allogeneic SCT based on data from Japan that showed an increased risk of severe graft-versus-host disease (GVHD) in patients who received mogamulizumab before allogeneic SCT.[10] The relevance of these findings in other countries and the impact of different GVHD prophylaxis regimens in this setting remains to be determined.
Sources: 10
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Brentuximab vedotin is a monoclonal antibody-drug conjugate directed at CD30 and is a treatment option for patients with ATL whose tumor expresses CD30.[11] Patients with ATL were included in a clinical trial of brentuximab vedotin that mostly involved patients with anaplastic large T-cell lymphoma. A statistical benefit for the very small ATL subgroup could not be established.[11][Level of evidence C3]
Sources: 11 · 11 · Level of evidence C3
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
In a multicenter phase II study (NCT01724177) of 26 patients with relapsed ATL, the overall response rate was 42% (95% CI, 23%–63%) in patients who received the immunomodulatory agent lenalidomide.[12][Level of evidence C3]
Sources: NCT01724177 · 12 · Level of evidence C3
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Valemetostat is a selective dual inhibitor of EZH1 and EZH2, which are important histone methyltransferases involved with chromatin folding.[13] A multicenter phase II study (NCT04102150) enrolled 25 patients with relapsed or refractory ATL, 24 of whom had prior therapy with mogamulizumab.[14] With a median follow-up of 6.5 months, the overall response rate was 48% (90% CI, 30.5%–65.9%). There were five complete remissions and seven partial remissions among the heavily pretreated patients.[14][Level of evidence C3] Responses were seen in patients with the acute, lymphoma, and chronic versions of ATL. Although approved for use in Japan, valemetostat is not approved by the FDA for use in the United States.
Sources: 13 · NCT04102150 · 14 · 14 · Level of evidence C3
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
The combination of zidovudine and interferon alfa has activity against ATL, especially among patients with the chronic and smoldering versions of ATL.[15,16] Durable remissions of 8 to 12 months and response rates of 20% to 40% have been reported for patients, some of whom had relapsed disease after prior chemotherapy,[15,16] and some with the acute and lymphoma subtypes of ATL.[17,18]
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
The acute and lymphoma types of ATL respond poorly to combination cytotoxic chemotherapy and allogeneic SCT, with a median OS under 1 year.[19-21] Less than 10% of patients who received combination therapy were alive after 4 years in one retrospective study.[21] Durable remissions have been reported after allogeneic SCT and even after subsequent donor lymphocyte infusion for relapses after transplant.[22-24][Level of evidence C3] Among 815 patients who underwent allogeneic SCT in two retrospective reviews, the 3-year OS rates were 36% and 26%.[25,26][Level of evidence C1]
Sources: 19 · 21 · 21 · 22 · 24 · Level of evidence C3 · 25 · 26 · Level of evidence C1
The cytotoxic chemotherapy backbone for patients with ATL in the United States and Europe is the CHOP or CHO(E)P regimen (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone). Brentuximab vedotin has been added to CHOP in rare cases when patients express CD30. For the acute and lymphoma versions of ATL, a series of clinical trials in Japan established VCAP-AMP-VECP as the standard first-line treatment.[2,27,28] This regimen has generally not been implemented outside of Asia since a trial comparing VCAP-AMP-VECP versus CHOP-14 did not show statistically improved OS (3-year OS rate, 24% vs. 13%; P = nonsignificant).
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Prolymphocytic leukemia (PLL) is a rare form of lymphocytic leukemia characterized by excessive prolymphocytes in the blood with a typical phenotype that is positive for CD19, CD20, and surface-membrane immunoglobulin and negative for CD5.[1] These patients demonstrate splenomegaly and poor response to low-dose or high-dose chemotherapy.[2,3]
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Cladribine appears to be an active agent (60% complete remission rate) for patients with de novo B-cell PLL.[4][Level of evidence C3] Anecdotal responses have been seen with venetoclax.[5][Level of evidence C3] Alemtuzumab, an anti-CD52 humanized monoclonal antibody, has been used for 76 patients with T-cell PLL after failure of previous chemotherapy (usually pentostatin or cladribine). The response rate was 51% (95% confidence interval, 40%–63%), and the median time to progression was 4.5 months (range, 0.1–45.4).[6][Level of evidence C3] These response rates have been confirmed by other investigators.[7] Patients with chronic lymphocytic leukemia (CLL) and prolymphocytoid transformation maintain the classic CLL phenotype and have a worse prognosis than patients with PLL.
Sources: 4 · Level of evidence C3 · 5 · Level of evidence C3 · 6 · Level of evidence C3 · 7
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Source: Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025. Captured 2026-09-09.
Treatment options for relapsed or refractory peripheral T-cell lymphoma include:
Combination chemotherapy.
GEMOX (gemcitabine, oxaliplatin, and dexamethasone).[3]
Sources: 3
DHAP (dexamethasone, high-dose cytarabine, and cisplatin).[4]
Sources: 4
Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone).[7]
Sources: 7
Antibody conjugates.
Antibody conjugates.
Brentuximab vedotin (for CD30-positive patients).
Histone deacetylase inhibitors.
Dihydrofolate reductase inhibitors.
Anti-CD52 monoclonal antibodies.
Anti-CD52 monoclonal antibodies.
Alemtuzumab (only available through a restricted distribution program).
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
ClinicalTrials.gov recordRecurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant...
ClinicalTrials.gov recordRelapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma
ClinicalTrials.gov recordAdult T-Cell Leukemia-Lymphoma
ClinicalTrials.gov recordExtranodal NK-T-Cell Lymphoma, Nasal Type
ClinicalTrials.gov recordExtranodal Natural Killer/T-Cell Lymphoma
ClinicalTrials.gov recordAdult T-cell Leukemia/Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma, T-Cell, Peripheral
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordPeripheral T-Cell Lymphoma
ClinicalTrials.gov recordAdult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL)
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordRelapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
ClinicalTrials.gov recordPeripheral T-Cell Lymphoma
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordPeripheral T-Cell Lymphoma
ClinicalTrials.gov recordMycosis Fungoides, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Peripheral T-Cell, Lymphomas: Non-Hodgkin Cutaneous Lymphoma
ClinicalTrials.gov recordAnaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma
ClinicalTrials.gov recordPeripheral T-Cell Lymphoma
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordLymphoma, T-cell, Peripheral
ClinicalTrials.gov recordAdult Nasal Type Extranodal NK/T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell...
ClinicalTrials.gov recordRelapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
ClinicalTrials.gov recordChildhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
ClinicalTrials.gov recordLymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordHodgkin Disease, Peripheral T Cell Lymphoma
ClinicalTrials.gov recordALK-activated Tumors
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordPeripheral T-Cell Lymphoma
ClinicalTrials.gov recordHodgkin Lymphoma, Anaplastic Large-cell Lymphoma
ClinicalTrials.gov recordLymphoma, T-Cell
ClinicalTrials.gov recordSolid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
ClinicalTrials.gov recordRelapsed or Refractory Peripheral T-Cell Lymphoma
ClinicalTrials.gov recordTumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor, Glioblastoma
ClinicalTrials.gov recordAnaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified,...
ClinicalTrials.gov recordPeripheral T-Cell Lymphoma
ClinicalTrials.gov recordPeripheral T-Cell Lymphoma (PTCL)
ClinicalTrials.gov recordT-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
ClinicalTrials.gov recordBlastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable, Primary Systemic Anaplastic Large Cell...
ClinicalTrials.gov recordRefractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordPreviously Untreated Peripheral T-cell Lymphoma
ClinicalTrials.gov recordLymphoma, T-Cell, Peripheral
ClinicalTrials.gov recordPeripheral T Cell Lymphoma
ClinicalTrials.gov recordPeripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma
ClinicalTrials.gov recordPeripheral T Cell Lymphoma
ClinicalTrials.gov recordHodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
ClinicalTrials.gov recordPeripheral T Cell Lymphoma, Transformed Mycosis Fungoides
ClinicalTrials.gov recordRelapsed or Refractory Peripheral T Cell Lymphoma
ClinicalTrials.gov recordPeripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma
ClinicalTrials.gov recordPeripheral T-cell Lymphoma
ClinicalTrials.gov recordRelapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
ClinicalTrials.gov recordRelapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordRelapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
ClinicalTrials.gov recordAnn Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma
Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma
Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma
Peripheral T-Cell Non-Hodgkin Lymphoma
Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [ see...
DailyMed labelFOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [ see Clinical Studies (14) ] ....
DailyMed labelPralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies...
DailyMed label